Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Ipsen enters into partnership agreement with Inspiration Biopharmaceuticals

Ipsen and Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that they have entered into a partnership to create a world leading hemophilia franchise. The partnership is designed to leverage combined expertise and resources to advance a broad portfolio of recombinant proteins, which address all major hemophilia disorders in a unique way by focusing on two significant unmet needs: wider access to treatment with coagulation factors and treatment for inhibitor complications.

21 Jan 2010

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office).

21 Jan 2010

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

Kolltan Pharmaceuticals, Inc., a next-generation oncology therapeutics company, announced today that it has raised $10 million in investments and related payments from an affiliate of Celtic Therapeutics Holdings L.P. (“Celtic Therapeutics”) and Tichenor Ventures, LLC.

20 Jan 2010

Fc engineering enhances antibody half-life

A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.

20 Jan 2010

Access Pharmaceuticals provides update on its Cobalamin insulin development program

ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.

20 Jan 2010

Media outlets examine efforts to develop malaria vaccines

Scientists have identified a group of proteins they say could form the basis of a malaria vaccine, Australia's ABC News reports. "However, they say more laboratory work and clinical trials need to be done, with a vaccine at least 10 years away," the news service reports (Macey, 1/19).

20 Jan 2010

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."

20 Jan 2010

CytoDyn commences enrollment in Cytolin clinical trial

Following approval of the Institutional Review Board, CytoDyn, Inc. has discharged its duty to register a clinical trial of Cytolin®, the Company’s lead product, with the government’s website at www.clinicaltrials.gov, ID NCT01048372. The public has online access to this federal database, which describes the key elements of clinical trials and their status.

19 Jan 2010

Affomix, City of Hope collaborate in exploring next generation sequencing using digital proteomics

Affomix Corporation, a pioneer in high performance antibody technology, announced today a collaboration with City of Hope focused on establishing the clinical utility of “digital proteomics” with next generation sequencers. One of the nation’s top cancer research and treatment centers, City of Hope is a leading provider of molecular diagnostic testing services and an innovator in clinical genetics research.

19 Jan 2010

New findings support the development of vaccine against malaria

Walter and Eliza Hall Institute researchers have uncovered a group of proteins that could form the basis of an effective vaccine against malaria.

19 Jan 2010

PATH MVI announces collaboration in development of malaria TBV

The PATH Malaria Vaccine Initiative (MVI) today announced a new collaboration to initiate development toward a vaccine that may eventually help eliminate and eradicate malaria. This collaboration with the Johns Hopkins Bloomberg School of Public Health (JHSPH) and the Sabin Vaccine Institute (Sabin) marks MVI's first investment in transmission-blocking vaccines (TBVs). This vaccine approach aims to stop the malaria parasite from developing in the mosquito, effectively blocking transmission of malaria from mosquitoes to humans. Malaria kills nearly 900,000 people per year, most of them children younger than age five.

18 Jan 2010

Sword Diagnostics launches Raman detection system for ultrasensitive immunoassays

Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.

18 Jan 2010

Researchers discover potential treatment for blinding disease

The discovery of an inflammatory mediator key to the blinding effects of diabetic retinopathy is pointing toward a potential new treatment, Medical College of Georgia researchers said.

18 Jan 2010

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Kenta Biotech today announced an agreement with Rentschler Biotechnologie for the development of a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).

18 Jan 2010

Role of H. pylori in autoimmune atrophic gastritis

Experimental animal studies have shown that H. pylori shares several antigenic regions in common with acid secreting cells in gastric mucosa. Antibodies triggered by H. pylori destroy acid secreting cells due to this antigenic mimicry.

17 Jan 2010

Multimmune GmbH and Boulder Diagnostics partner to develop HSP70 lateral flow point of care test

Multimmune GmbH and Boulder Diagnostics Inc. announce today the joint development of an HSP70 lateral flow point of care test. Multimmune has discovered that many tumor types display the heat shock protein 70 (Hsp70) on the cell surface.

13 Jan 2010

University of Leicester study provides new insights into preventer and reliever treatments for asthma

A new study at the University of Leicester is probing why asthma relief inhalers might actually make asthma worse- and what can be done about it.

13 Jan 2010

Research reveals how cancers shield themselves from immune attack

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site.

13 Jan 2010

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Novavax, Inc. announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats. Results from this study are needed to support an Investigational New Drug (IND) application to advance this novel recombinant F protein particle based RSV (RSV-F) vaccine candidate into clinical development. This vaccine candidate is composed of recombinant 'F' or 'fusion' protein of RSV which is used by the virus to infect and fuse with cells in the respiratory tract and cause disease.

13 Jan 2010

TTI enters into definitive license agreement with Biogen Idec

Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec , granting the latter exclusive worldwide rights to one of Trillium's development programs.

12 Jan 2010

Antibody News and Research

Further Reading

Ipsen enters into partnership agreement with Inspiration Biopharmaceuticals

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

Fc engineering enhances antibody half-life

Access Pharmaceuticals provides update on its Cobalamin insulin development program

Media outlets examine efforts to develop malaria vaccines

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

CytoDyn commences enrollment in Cytolin clinical trial

Affomix, City of Hope collaborate in exploring next generation sequencing using digital proteomics

New findings support the development of vaccine against malaria

PATH MVI announces collaboration in development of malaria TBV

Sword Diagnostics launches Raman detection system for ultrasensitive immunoassays

Researchers discover potential treatment for blinding disease

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Role of H. pylori in autoimmune atrophic gastritis

Multimmune GmbH and Boulder Diagnostics partner to develop HSP70 lateral flow point of care test

University of Leicester study provides new insights into preventer and reliever treatments for asthma

Research reveals how cancers shield themselves from immune attack

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

TTI enters into definitive license agreement with Biogen Idec

Monoclonal Antibody Manufacturing Trends eBook eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News